Wilson Therapeutics AB

Wilson Therapeutics AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017

Thu, Nov 23, 2017 08:00 CET

Ready for Phase 3July 1 – September 30, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 29.4 M (loss: 31.9) · Loss per share, before and after dilution, totaled SEK 1.14 (loss: 1,24) · At September 30, cash and cash equivalents amounted to SEK 277.1 M (416.5) January 1 – September 30, 2017 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 115.4 M (loss: 81.1) · Loss per share, before and after dilution, totaled SEK 4.49 (loss: 5.81) Significant events during the period January 1 – September 30, 2017 ·

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017

Twitter